CD274 and thyroid cancer, nonmedullary, 2: The phase Ib KEYNOTE-028 trial assessed the efficacy of pembrolizumab in patients with PD-L1+ (membranous staining on ≥1% with the 22C3 antibody) locally advanced or metastatic FTC or PTC.